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Background: Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor
approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma
who have received ≥ 1 prior systemic therapy and patients with peripheral T-cell lymphoma (PTCL) who have
received ≥ 1 prior therapy. Approval for PTCL was based on results (n = 130; median follow-up, 13.4 months) from
the pivotal study of romidepsin for the treatment of relapsed/refractory PTCL. The objective is to present updated
data (median follow-up, 22.3 months) and to characterize patients who achieved long-term responses (≥ 12
months) to romidepsin.
Methods: Patients with PTCL who relapsed from or were refractory to ≥ 1 prior systemic therapy received
romidepsin 14 mg/m2 as a 4-hour intravenous infusion on days 1, 8, and 15 every 28 days for up to 6 cycles;
patients with response or stable disease could continue romidepsin beyond 6 cycles. The primary endpoint was rate
of confirmed/unconfirmed complete response (CR/CRu) determined by an Independent Review Committee.
Secondary endpoints included objective response rate (ORR) and duration of response (DOR). For patients who
achieved CR/CRu, baseline characteristics by DOR (≥ 12 vs < 12 months) were examined.
Results: The ORR to romidepsin was 25%, including 15% with CR/CRu. The median DOR for all responders was 28
months (range, < 1-48+) and was not reached for those who achieved CR/CRu. Patients with lack of response or
transient response to prior therapy achieved durable responses with romidepsin. Of the 19 patients who achieved
CR/CRu, 10 had long-term (≥ 12 months) responses; none of the baseline characteristics examined—including
heavy pretreatment, response to prior therapy, or advanced disease—precluded long-term responses to romidepsin.
With a median progression-free survival of 29 months, patients who achieved CR/CRu for ≥ 12 months had
significantly longer survival vs those with CR/CRu for < 12 months or < CR/CRu. Extended treatment and longer
follow-up did not affect the reported safety profile of romidepsin.
Conclusions: Treatment with romidepsin leads to highly durable responses in a subset of patients with relapsed/
refractory PTCL, with responses ongoing as long as 48 months.
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Peripheral T-cell lymphoma (PTCL) is an aggressive,
uncommon form of non-Hodgkin lymphoma (NHL)
that is typically associated with a poor prognosis [1-3].
PTCL comprises many subtypes that vary in morph-
ology, biology, and prognosis [1,2]. The most common
subtypes globally are PTCL–not otherwise specified (NOS),
angioimmunoblastic T-cell lymphoma (AITL), and ana-
plastic large cell lymphoma (ALCL) [2]. In western
countries, PTCL accounts for 15% to 20% of aggressive
lymphomas and 5% to 10% of NHL diagnoses. The pre-
valence is higher in Asia, with approximately 15% to
20% of all lymphomas classified as PTCL or natural
killer/T-cell lymphoma [2,4-6]. Some of this variation
may be a result of exposure or genetic susceptibility
to pathogenic agents such as human T-lymphotropic
virus-1 and Epstein-Barr virus in Asia [2,5,7].
There is no current standard of care for patients with
most subtypes of PTCL, and no agents have been ap-
proved specifically for use as first-line treatment of
PTCL [3,8]. In the first line, most patients receive in-
duction chemotherapy regimens derived from studies
of B-cell lymphomas, most commonly anthracycline-
containing regimens such as CHOP (cyclophosphamide,
doxorubicin, vincristine, prednisone) [1-3,8-11]. Although
most patients achieve a response with induction chemo-
therapy, responses are typically brief and many patients
experience relapse or become refractory to treatment
[1-3,9,10]. The role of stem cell transplantation (SCT)
for patients with PTCL is yet to be clearly determined
and, currently, only a minority (< 20%) of patients undergo
SCT [9-11]. Many patients with PTCL who receive SCT
experience disease relapse after transplantation [12].
Romidepsin—a structurally unique, potent, bicyclic
class 1 selective histone deacetylase inhibitor [13-15]—
is approved for the treatment of both patients with cu-
taneous T-cell lymphoma who have received ≥ 1 prior
systemic therapy and patients with PTCL who have re-
ceived ≥ 1 prior therapy [16]. Approval in PTCL was
primarily based on results from a phase 2, single-arm,
open-label study in relapsed/refractory PTCL (GPI-06-
0002) [17].
For romidepsin, data from GPI-06-0002 (n = 130) based
on an October 2010 cutoff (median follow-up, 13.4 months)
were presented in the package insert [16] and published
manuscript [17] and include a 25% objective response rate
(ORR), 15% confirmed/unconfirmed complete response
(CR/CRu) rate, and median duration of response (DOR) of
17 months [17]. As of the October 2010 data cutoff, 17 of
19 patients who had experienced CR/CRu had not pro-
gressed [17]. The objective of this manuscript is to present
updated GPI-06-0002 efficacy data and characteristics of
patients who achieved long-term responses (≥ 12 months)




A total of 131 patients were enrolled; 130 had histologi-
cally confirmed PTCL by central review, and 1 had a diag-
nosis of diffuse large B-cell lymphoma by central review
and was excluded from the baseline measurements and
efficacy assessments. Patient demographics and baseline
characteristics were previously described in detail (n =
130) [17]. Briefly, most patients had an Eastern Coopera-
tive Oncology Group (ECOG) performance status of 1 to
2 (64%), International Prognostic Index ≥ 2 (76%), and
stage III or IV disease (70%). Thirty-six patients (28%) had
bone marrow involvement. Patients had received a median
of 2 (range, 1–8) prior systemic therapies; 37% of patients
had received ≥ 3 therapies, and 16% had received prior
autologous SCT. The most common PTCL subtypes were
PTCL–NOS, AITL, and anaplastic lymphoma kinase
(ALK)-1–negative ALCL; baseline characteristics were
similar across these common PTCL subtypes.
Efficacy
Response rates
Response rates as assessed by the IRC were unchanged
compared with the primary publication [17]: ORR of 25%
(33 of 130), including CR/CRu in 15% of patients (19 of
130). At a median follow-up of 22.3 months, all patients
received a median of 2 treatment cycles (range, < 1–54),
whereas patients who achieved a response (CR/CRu or
partial response [PR]; n = 33) received a median of 8 treat-
ment cycles (range, < 1–54) and patients who achieved a
CR/CRu (n = 19) received a median of 19 treatment cycles
(range, 2–54). Response rates were similar across the 3
most common PTCL subtypes (Table 1), and no signifi-
cant differences in ORR or rates of CR/CRu were
observed.
Durability of responses
Most responses were noted at the first response assessment
(2 months), and the median time to response as assessed
by the IRC was 1.8 months (range, 1.4-5.3 months). The
median DOR for all patients who achieved a response by
IRC (n = 33) was 28 months (range, < 1-48+) and had not
been reached (range, < 1-48+) for those who achieved CR/
CRu (n = 19). One patient with a reported DOR < 1 month
discontinued treatment to receive SCT after the first re-
sponse assessment of CR. Of the 19 patients who achieved
CR/CRu, 53% had a DOR ≥ 12 months and 32% had a
DOR ≥ 24 months. Responses were durable across the 3
most common PTCL subtypes (Figure 1), and no statisti-
cally significant differences in DOR were observed. For
patients with progressive disease (PD) to their last prior
Table 1 Overall Response Rates (IRC)
Best response, n (%) PTCL-NOS AITL ALK-1–Negative ALCL
(n = 69) (n = 27) (n = 21)
ORR 20 (29) 8 (30) 5 (24)
CR/CRu 10 (14) 5 (19) 4 (19)
PR 10 (14) 3 (11) 1 (5)
SD 16 (23) 9 (33) 5 (24)
Disease control (ORR + SD90) 34 (49) 12 (44) 8 (38)
PD/NEa 33 (48) 10 (37) 11 (52)
Abbreviations: AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, CR/CRu confirmed/unconfirmed
complete response, IRC Independent Review Committee, NE not evaluable, ORR objective response rate, PD progressive disease, PR partial response, PTCL-NOS
peripheral T-cell lymphoma–not otherwise specified, SD stable disease, SD90 SD for ≥ 90 days.
aInsufficient efficacy data to determine response because of early termination.
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yet been reached for all patients who achieved a response
(n = 14) or for patients wxho achieved CR/CRu (n = 9).
Patients with a lack of response (n = 13) or transient
response (n = 8; median DOR, 4.5 months [range, 2–
23 months]) to prior therapy (most commonly CHOP
[n = 7], GVD [gemcitabine, vinorelbine, doxorubicin; n = 2],
ICE [ifosfamide, carboplatin, etoposide; n = 2], ESHAP
[etoposide, methylprednisolone, high-dose cytarabine, cis-
platin; n = 2], or pralatrexate [n = 2]), by investigator assess-
ment, were able to achieve durable CR/CRu to romidepsin
(median DOR, 14 months [range 1-48+ months]) across
the 3 most common PTCL subtypes (Figure 2). Patients
who achieved CR/CRu with a reported DOR < 12 months
(investigator assessment) discontinued treatment for the
following reasons: adverse event (AE; n = 2), patient or in-
vestigator decision to stop therapy while in CR, physician
decision, and SCT (each n = 1).
Analysis of long-term responders
Of the 19 patients who achieved CR/CRu (Figure 3), 16
(84%) had not experienced PD per the IRC at a medianFigure 1 Durations of response for the 3 most common subtypes of P
censored patient.follow-up of 25.8 months. For those 16 patients, the DOR
at time of censoring ranged from < 1 month to 48+
months. Ten of 19 patients who achieved CR/CRu were
considered long-term responders (responses ≥ 12 months).
Of these 10 patients, 1 had IRC-confirmed PD; 3 were
censored as a result of investigator-assessed PD (n = 1),
physician decision (n = 1), or AE (n = 1); and 6 continued
romidepsin treatment for ≥ 2 years (received 25, 27, 29, 36,
36, and 53 cycles as of the data cutoff). Nine of the 19 pa-
tients who achieved CR/CRu had a reported DOR < 12
months. Two had IRC-confirmed PD, and 7 were censored
because investigator-assessed PD (n = 1), SCT (n = 2), phys-
ician decision (n = 2), or patient decision (n = 2). None
of the baseline characteristics examined—including heavy
pretreatment (≥ 3 prior therapies), response to prior ther-
apy, or advanced disease—precluded long-term responses
to romidepsin (Table 2).
Achievement of CR/CRu was associated with prolonged
progression-free survival (PFS; median 29 months) and
overall survival (OS; median not reached) compared with
patients with a response < CR/CRu. Furthermore, achieve-
ment of CR/CRu at ≥ 12 months was associated withTCL in patients who achieved a response (CR or PR). ◦ Indicates a
Figure 2 Durations of response for patients who achieved CR/CRu on romidepsin (investigator assessed; n = 21). Only investigators assessed
DOR for prior therapy (for patients with PR or CR on prior therapy). Arrows indicate that the patient was censored while in response. * Indicates that
the patient received combination chemotherapy as the last prior therapy. NR indicates that the response to prior therapy was not reported.
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CR/CRu at < 12 months (Figure 4, Table 3; P < .05). Pa-
tients who achieved PR or stable disease (SD) for ≥ 90 days
(SD90) had similar long-term outcomes. For all patients,
median PFS and OS were 4 months and 11.3 months,
respectively.Figure 3 Durations of response for patients who achieved CR/CRu on
long-term responses (duration≥ 12 months). Of the 2 patients that receive
autologous for 1 patient, and not reported for 1 patient.Safety
As previously reported, the most common AEs included
gastrointestinal disturbances, hematologic abnormalities,
asthenic conditions, and infections (all types pooled) [17].
Reported electrocardiogram (ECG) abnormalities were un-
common, with no concurrent symptoms of syncope or otherromidepsin (IRC). The vertical line separates the 10 patients with
d stem cell transplant after romidepsin, type of transplant was
Table 2 Key Baseline Characteristics by Duration of CR/CRu
CR/CRu ≥ 12 months (n = 10) CR/CRu < 12 months (n = 9) P value
Male sex, n (%) 7 (70) 5 (56) .65
Median age, years (range) 61.5 (47–78) 57.0 (37–74) .43
ECOG performance status, n (%)
0 3 (30) 4 (44) .57
1 6 (60) 3 (33)
2 1 (10) 2 (22)
IPI score, n (%)
< 2 2 (20) 1 (11) 1.00
≥ 2 8 (80) 8 (89)
Prior systemic therapies, n (%)
1 2 (20) 3 (33) .38
2 3 (30) 3 (33)
3 0 2 (22)
4 3 (30) 1 (11)
> 4 2 (20) 0
Best response to most recent prior therapy, n (%)
CR/CRu/PR 2 (20) 6 (67) .07
< PR 8 (80) 3 (33)
Disease stage at diagnosis, n (%)
I/II 0 (0) 4 (44) .03
III/IV 10 (100) 5 (56)
PTCL subtype, n (%)
PTCL-NOS 5 (50) 5 (56) .34
AITL 4 (40) 1 (11)
ALK-1–negative ALCL 1 (10) 3 (33)
Bone marrow involvement, n (%) 5 (50) 2 (22) .35
Elevated LDH, n (%) 5 (50) 8 (89) .14
Platelet count x 109/L, median (range) 199 (101–307) 172 (99–649) .42
Abbreviations: AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, CR complete response, CR/CRu
confirmed/unconfirmed complete response, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, LDH lactate dehydrogenase, NOS not
otherwise specified, PR partial response, PTCL peripheral T-cell lymphoma.
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no clinically significant changes in QT intervals across treat-
ment cycles were found [17]. The AE profile was similar
across the 3 most common PTCL subtypes. Longer treat-
ment duration did not affect the safety profile of romidepsin.
Grade ≥ 3 AEs occurred with the highest incidence during
cycles 1 to 2 (Figure 5). After cycle 18, ≤ 10 patients re-
mained on treatment, and most grade ≥ 3 AEs reported were
from 1 patient with grade ≥ 3 vomiting, cellulitis, deep vein
thrombosis, and/or constipation in cycles 22, 24, 27, 31, and
32. In addition, one patient had grade ≥ 3 pyrexia in cycle
22 and one patient had grade ≥ 3 pneumonia in cycle 24.
Discussion
Since 2009, 3 agents have been approved in the United
States for patients with relapsed/refractory PTCL [16,18,19].Pralatrexate, a folate analogue, is approved for the treat-
ment of patients with relapsed or refractory PTCL [18]
based on a single-arm phase 2 study showing 29% ORR,
including 11% CR (n = 109) and a median DOR of
10.1 months [20]. Brentuximab vedotin, a CD30-directed
antibody-drug conjugate, is approved for the treatment of
patients with systemic ALCL after failure of ≥ 1 prior mul-
tiagent chemotherapy regimen [19]. ALCL is a common
subtype of PTCL (approximately 25% of cases in North
America) that is uniformly CD30+ [2,21]. Approval was
based on an 86% ORR, including a 57% CR (n = 58) [21]
and a median DOR of 13.2 months [22]. In patients with
relapsed/refractory PTCL, romidepsin demonstrated a 25%
ORR, including 15% CR/CRu and a median DOR of 28
months for all responders. Responses were rapid with a me-
dian time to objective response of 1.8 months. Long-lasting
Figure 4 Survival (PFS, OS) by quality of response to romidepsin.
Table 3 Survival (PFS, OS) by Quality of Response to Romidepsin
Objective
responders
CR/CRu CR/CRu PR SD90 SD < 90/
PD/NE≥ 12 months < 12 months
(CR/CRu + PR; n = 33) (n = 10) (n = 9) (n = 14) (n = 23) (n = 74)
Median OS, months (range) 30 NR NR 18 NR 5
(2.0-49.5) (21.2-49.5) (9.2-32.0) (2.0-38.8) (8.1-44.6) (0.3-29.3)
Median PFS, months, (range) 20 29 13 7 7 2
(1.6-49.8) (17.6-49.8) (1.6-26.0) (1.9-18.1) (3.3-37.7) (0.3-14.4)
Abbreviations: CR/CRu confirmed/unconfirmed complete response, NR not reached, OS overall survival, PD progressive disease, PFS progression-free survival,
PR partial response, SD stable disease, SD90 SD ≥ 90 days.
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Figure 5 Incidence of grade ≥ 3 AEs by treatment cycle. Cycles in which no grade≥ 3 AEs were reported are not included.
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patients refractory to their last prior therapy.
Romidepsin has demonstrated comparable efficacy across
the 3 most common PTCL subtypes. Although pralatrexate
has general approval for the treatment of PTCL, based on
results from the pivotal study in relapsed/refractory PTCL
[20], National Comprehensive Cancer Network guidelines
report that pralatrexate has demonstrated limited activity
in AITL [8]. Brentuximab vedotin has demonstrated con-
siderable activity in ALCL [21], and responses have also
been seen in CD30+ cases of other NHL subtypes (includ-
ing AITL) [23]; however, its utility in non-CD30+ PTCLs is
unknown.
More than one-half of the patients with relapsed/re-
fractory PTCL who achieved CR/CRu on romidepsin ex-
perienced long-term responses (≥ 12 months). Complete
responses were achieved in patients with typically poor
prognostic factors, and none of the examined patient or
disease characteristics predicted failure to achieve long-
term remission. Achievement of CR/CRu was associated
with prolonged survival, and achievement of SD90 led to
survival rates similar to the achievement of PR.
Amendments to the study protocol allowed for main-
tenance with 2 romidepsin doses per cycle for patients
who received ≥ 12 treatment cycles and with 1 dose per
cycle for patients who received ≥ 24 treatment cycles and
had received 2 doses for ≥ 6 treatment cycles.
Extended dosing of romidepsin was tolerated; the most
grade ≥ 3 AEs were observed in the first 2 cycles of treat-
ment. ECG abnormalities were uncommon, and no clin-
ically significant changes were observed across treatment
cycles [17]. An early analysis of a post-marketing QT
study demonstrated that romidepsin does not have a
concentration-dependent effect on the QTc interval (in-
cluding at exposures more than 2-fold the approved dos-
ing), and while clinically insignificant changes in QTcwere reported, these changes were attributable to anti-
emetic premedication [24]. Romidepsin was associated with
a delayed concentration-dependent increase in heart rate
with a maximum mean increase of 20 beats per minute 6
hours after the start of a 4-hour romidepsin infusion [16].
Publication of the final analysis of the QT study is ongoing.
A SEER (Surveillance and Epidemiology End Results)
database analysis from 1992 to 2009 showed that, with the
exception of ALCL, the incidence of common PTCL sub-
types has greatly increased over the past few decades (the
combined rate more than tripled from 1992 to 2009) [25].
However, over this same time period, survival times did not
increase [25] as they have for patients with B-cell lymph-
oma [26]. Despite poor outcomes, anthracycline-based regi-
mens continue to be commonly used for the treatment of
PTCL [1-3,8-11]. With the approval of 3 novel agents since
2009 [16,18,19], it is hoped that a trend toward improved
survival will begin to emerge. Current studies are evaluating
the combination of these newly approved agents with che-
motherapeutic regimens. Preliminary results from a phase
1B study of romidepsin in combination with CHOP for the
first-line treatment of patients with PTCL (14 evaluable pa-
tients) demonstrated an ORR of 78%, including 57% CR
[27], and a phase 2 extension study is ongoing. A separate
phase 3 study of romidepsin + CHOP vs CHOP alone in
frontline PTCL is also ongoing [28]. Preliminary results
from a phase 1 study of brentuximab vedotin with CH-P
(CHOP minus vincristine) for the first-line treatment of pa-
tients with higher-risk systemic ALCL and other CD30+
mature natural killer/T-cell lymphomas (n = 26) demon-
strated an ORR of 100%, including 88% CR [29]. A phase 2
study of CEOP (cyclophosphamide, etoposide, vincristine,
prednisone) alternating with pralatrexate for the first-line
treatment of PTCL is underway [30], and a separate phase
3 study will investigate pralatrexate vs observation mainten-
ance therapy following CHOP-based induction in patients
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trials is essential to determine whether any of these combi-
nations leads to durable responses.
Conclusions
The results presented herein demonstrate that treatment
with single-agent romidepsin leads to highly durable re-
sponses in patients with relapsed/refractory PTCL, includ-
ing patients with the 3 major PTCL subtypes, patients
who received several prior systemic therapies, patients
with advanced disease, and, importantly, patients refrac-
tory to their last prior therapy. Patients with long-term
responses to romidepsin can successfully continue on
romidepsin, with or without reducing dose frequency, to
maintain response at the discretion of the investigator.
Whether combining romidepsin with regimens that in-
duce higher initial response rates (eg, CHOP) will enhance
the durability of these responses and lead to prolonged
survival, both in relapsed/refractory patients and in those
with newly diagnosed disease, warrants further investi-
gation. Additionally, the potential for use of romidepsin as
maintenance therapy after chemotherapy induction or
after consolidation with high-dose chemotherapy followed
by SCT should be examined, because long-term tolerabil-
ity has been demonstrated.
Methods
Study design and eligibility criteria
GPI-06-0002 is a prospective, single-arm, open-label, inter-
national phase 2 study that was previously described in de-
tail [17]. Briefly, eligibility criteria included adult patients
with PTCL relapsed or refractory to ≥ 1 systemic therapy,
adequate bone marrow and organ function, and measur-
able disease according to International Working Group
(IWG) criteria [32] and/or measurable cutaneous disease
and an ECOG performance status of 0 to 2 at enrollment.
Concomitant use of drugs that could significantly prolong
the QTc interval was not allowed, and patients with known
significant cardiac abnormalities were excluded. Hypo-
kalemia and hypomagnesemia can be associated with
ECG abnormalities [33]; therefore, patients must have
had serum potassium concentrations ≥ 3.8 mmol/L and
serum magnesium concentrations ≥ 0.85 mmol/L; low
levels could be corrected by supplementation to meet
inclusion criteria.
Patients received romidepsin 14 mg/m2 (4-hour intra-
venous infusion) on days 1, 8, and 15 of 28-day cycles
(same dose and schedule as those approved for patients
with relapsed/refractory cutaneous T-cell lymphoma or
PTCL [16]) for up to 6 cycles. Patients with SD or re-
sponse could continue to receive treatment beyond 6 cy-
cles at the discretion of the patient and investigator. The
protocol was amended to allow for (but not mandate)
maintenance dosing of romidepsin (2 doses per cycle)for patients treated for ≥ 12 cycles. Patients who initiated
maintenance dosing must continue to receive ≥ 2 doses
per cycle through at least cycle 24 and must have re-
ceived 2 doses per cycle for ≥ 6 months prior to a reduc-
tion to 1 dose per cycle.Response assessments and study endpoints
The efficacy and safety assessments conducted and the
response criteria used were previously described in detail
[17,32]. Briefly, response assessments were performed every
2 cycles by both investigators and an IRC (composed of
both radiologists and hematologic oncologists) according
to the 1999 IWG criteria guidelines for response assess-
ments for NHL (IWG-NHL) [32]. The primary endpoint
was rate of CR/CRu as determined by IRC. Secondary end-
points included ORR, DOR (time from the first date of re-
sponse to the date of PD or date of last study assessment),
and time to disease progression by IRC and investigators’
assessments; change in ECOG performance status; toler-
ability; and safety. Time to response, PFS, and OS were also
assessed.Statistical methods
This study is ongoing, but December 31, 2011, was the
cutoff date for this analysis. Patients who withdrew with-
out PD were to be followed every 2 months until PD,
withdrawal from study, or start of alternate therapy. All de-
scriptive statistical analyses were performed by using SAS
statistical software version 9.2 (SAS Institute, Cary, NC).
Time-to-event data were summarized by Kaplan-Meier
methods.
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